Table 1.

Characteristics of currently available rotavirus vaccines.

Trade name	Manufacturer	Year of WHO pre-qualification	Doses	Composition	Form	Vaccine efficacy*	Post-licensure vaccine effectiveness* (VE)
Globally licensed
Rotarix	GSK	2009	3	G1P[8]	Liquid	LMC: 90% MMC: 78% HMC: 54%[15]	LMC: 83% MMC: 67% HMC: 58%[16]
RotaTeq	Merck	2008	2	G1, G2, G3, G4, P[8]	Liquid	LMC: 94% MMC: 81% HMC: 44%[15]	LMC: 85% HMC: 45%[16]
Rotavac	Bharat Biologicals	2018	3	G9P[11]	Liquid (frozen) and nonfrozen liquid (Rotavac 5D)	India: 54%[15]	VE studies are ongoing [9]
Rotasiil	Serum Institute of India	2018 (lyophilized) 2021 (liquid)	3	G1, G2, G3, G4, G9	Lyophilised and liquid forms available	India & Niger: 44%[15]	VE studies are ongoing
Nationally licensed
Rotavin-M1	POLYVAC	N/A	3	G1P[8]	Liquid (frozen) and nonfrozen liquid (Rotavin)	None published; IgA seroconversion 73%[53]	VE studies are ongoing
Lanzhou Lamb Rotavirus Vaccine	Lanzhou Institute of Biological Products	N/A	1 annually age 2 months to 3 years	G10P[15]	Liquid	Any severity: 57% Severe RVGE: 70% Inpatient RVGe: 74%[63]	35%―73% [52, 60, 61]

LMC=low-mortality countries; MMC=medium-mortality countries; HMC=high mortality countries;

^*against severe rotavirus gastroenteritis, per protocol analysis, unless otherwise noted